Is it now the time to update treatment protocols for lymphomas with new anti-virus systems?

Leukemia

Volumn 18, Issue 10, 2004, Pages 1572-1575

  Luppi, M ^a   Barozzi, P ^a   Potenza, L ^a   Riva, G ^a   Morselli, M ^a   Torelli, G ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALPHA INTERFERON; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; ARSENIC TRIOXIDE; CIDOFOVIR; DNA POLYMERASE; FOSCARNET; GANCICLOVIR; INTERFERON; NUCLEOSIDE ANALOG; PYROPHOSPHORIC ACID DERIVATIVE; RIBAVIRIN; RITUXIMAB; THYMIDINE DERIVATIVE; THYMIDINE KINASE; VIRUS ENZYME; ZIDOVUDINE;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER RESISTANCE; CARCINOGENESIS; CLINICAL PROTOCOL; CLINICAL TRIAL; CYTOTOXICITY; DISEASE ASSOCIATION; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; LYMPHOMA; MAINTENANCE THERAPY; MANTLE CELL LYMPHOMA; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS LOAD;

EID: 6344233172     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403447     Document Type: Article

References (33)

1. Kelaidi C, Rollot F, Park S, Tulliez M, Christoforov B, Calmus Y et al. Response to antiviral treatment in hepatitis C virus-associated marginal zone lymphomas. Leukemia 2004; 18: 1711-1716.
2. Hermine O, Lefrere F, Bronowicki JP, Mariette X, Jondeau K, Eclache-Saudreau V et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 2002; 347: 89-94.
3. Arcaini L, Paulli M, Boveri E, Vallisa D, Bernuzzi P, Orlandi F et al. Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting features but similar morphologic and phenotypic profiles. Cancer 2004; 100: 107-115.
4. Pitini V, Arrigo C, Righi M, Scaffidi M, Sturniolo G. Systematic screening for HCV infection should be performed in patients with splenic marginal zone lymphoma. Br J Haematol 2004; 124: 252-253.
5. Levine AM, Shimodara S, Lai MMC. Treatment of HCV-related mantle-cell lymphoma with ribavirin and pegylated interferon alpha. N Engl J Med 2004; 349: 2078-2079.
6. Berger F, Felman P, Thieblemont C, Pradier T, Baseggio L, Bryon PA et al. Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients. Blood 2000; 95: 1950-1956.
7. Zuckerman F, Zuckerman T, Sahar D, Streichman S, Attias D, Sabo E et al. The effect of antiviral therapy on t(14;18) translocation and immunoglobulin gene rearrangement in patients with chronic hepatitis C virus infection. Blood 2001; 97: 1555-1559.
8. Mazzaro C, Franzin F, Tulissi P, Pussini E, Crovatto M, Carniello GS et al. Regression of monoclonal B-cell expansion in patients affected by mixed cryoglobulinemia responsive to alpha-interferon therapy. Cancer 1996; 77: 2604-2613.
9. Evans AS, Mueller NE. Viruses and cancer: causal associations. Ann Epidemiol 1990; 1: 71-92.
10. Luppi M, Negrini R. MALT lymphomas: epidemiology and infectious agents. In: Zucca E, Bertoni F (eds). MALT Lymphomas, 2002. Eurekah.com. Georgetown, TX, USA: Landes/Eurekah.
11. Rabkin CS, Tess BH, Christianson RE, Wright WE, Waters DJ, Alter HJ et al. Prospective study of hepatitis C viral infection as risk factor for subsequent B cell neoplasia. Blood 2002; 99: 4240-4242.
12. Mele A, Pulsoni A, Bianco E, Musto P, Szkio A, Sanpaolo MG et al. Hepatitis C virus and B-cell non Hodgkin lymphomas: an Italian multicenter case-control study. Blood 2003; 102: 996-999.
13. Ohsawa M, Tomita Y, Hashimoto M, Kanno H, Aozasa K. Hepatitis C viral genome in a subset of primary hepatic lymphomas. Mod Pathol 1998; 11: 471-478.
14. Swaminathan S. Molecular biology of Epstein-Barr virus and Kaposi's sarcoma-associated herpesvirus. Sem Hematol 2003; 40 107-115.
15. Quinn ER, Chan CH, Hadlock KG, Foung SK, Flint M, Levy S. The B-cell receptor of a hepatitis C virus (HCV)-associated non-Hodgkin lymphoma binds the viral E2 envelope protein, implicating HCV in lymphomagenesis. Blood 2001; 98: 3745-3749.
16. Hermouet S, Corre I, Gassin M, Bigot-Corbel E, Sutton CA, Casey JW. Hepatitis C virus, human herpesvirus 8, and the development of plasma-cell leukaemia. N Engl J Med 2003; 348: 178-179.
17. Weissman IL, McGrath MS. Retrovirus lymphomagenesis: relationship of normal immune receptors to malignant cell proliferation. Curr Top Microbiol Immunol 1982; 98: 103-112.
18. Mann DL, DeSantis P, Mark G, Pfeifer A, Newman M, Gibbs N et al. HTLV-I-associated B-cell CLL: indirect role for retrovirus in leukemogenesis. Science 1987; 236: 1103-1106.
19. Machida K, Cheng KT-N, Sung VM-H, Shimodaira S, Lindsay KL, Levine AM et al. Hepatitis C virus induces a mutator phenotype: enhanced mutations of immunoglobulin and protooncogenes. Proc Natl Acad Sci USA 2004; 101: 4262-4267.
20. Meijer E, Dekker AW, Weersink AJL, Rozenberg-Arska M, Verdonck LF. Prevention and treatment of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of bone marrow and solid organ transplants. Br J Haematol 2002; 119: 596-607.
21. Oertel SH, Anagnostopoulos I, Hummel MW, Jonas S, Riess HB. Identification of early antigen BZLF/ZEBRA protein of Epstein-Barr virus can predict the effectiveness of antiviral treatment in patients with post-transplant lymphoproliferative disease. Br J Haematol 2002; 118: 1120-1123.
22. Schmidt W, Anagnostopoulos I, Scherubi H. Virostatic therapy for advanced lymphoproliferation associated with Epstein-Barr virus in an HIV-infected patient. N Engl J Med 2000; 342: 440-441.
23. Schneider U, Ruhnke M, Delecluse HJ, Stein H, Huhn D. Regression of Epstein-Barr virus associated lymphoproliferative disorders in patients with acquired immunodeficiency syndrome during therapy with foscarnet. Ann Hematol 2000; 79: 214-216.
24. Pastore RD, Chadburn A, Kripas C, Schattner EJ. Novel association of haemophagocytic syndrome with Kaposi's sarcoma-associated herpesvirus-related primary effusion lymphoma. Br J Haematol 2002; 111: 1112-1115.
25. Hocqueloux L, Agbalika F, Oksenhendler E, Molina J-M. Long term remission of an AIDS-related primary effusion lymphoma with antiviral therapy. AIDS 2001; 15: 280-282.
26. Lee RK, Cai JP, Deyev V, Gill PS, Cabral L, Wood C et al. Azidothymidine and interferon-alpha induce apoptosis in herpesvirus-associatedlymphomas. Cancer Res 1999; 59: 5514-5520.
27. Ghosh SK, Wood C, Boise LH, Mian AM, Deyev VV, Feuer G et al. Potentiation of TRAIL-induced apoptosis in primary effusion lymphoma through azidothymidine-mediated inhibition of NF-kB. Blood 2003; 101: 2321-2327.
28. Casper C, Nichols G, Huang M-L, Corey L, Wald A. Remission of HHV-8 and HIV-associated multicentric Castleman disease with ganciclovir treatment. Blood 2004; 103: 1632-1634.
29. Kedes DH, Ganem D. Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. Implications for potential therapy. J Clin Invest 1997; 99: 2082-2086.
30. Gill PS, Harrington Jr W, Kaplan MH, Ribeiro RC, Bennett JM, Liebman HA et al. Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N Engl J Med 1995; 332: 1744-1748.
31. Hermine O, Bouscary D, Gessain A, Turlure P, Leblond V, Franck N et al. Brief report: treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alfa. N Engl J Med 1995; 332: 1749-1751.
32. Hermine O, Dombret H, Poupon J, Arnulf B, Lefrere F, Rousselot P et al. Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed/refractory adult T-cell leukemia/lymphoma. Hematol J 2004; 5: 130-134.
33. Jaffe FS. Common threads of mucosa-associated lymphoid tissue lymphoma pathogenesis: from infection to translocation. J Natl Cancer Inst 2004; 96: 571-573.